Shares of MEI Pharma, Inc. (NASDAQ:MEIP – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.02 and traded as low as $2.84. MEI Pharma shares last traded at $2.85, with a volume of 15,859 shares.
Wall Street Analyst Weigh In
Several brokerages have commented on MEIP. StockNews.com started coverage on MEI Pharma in a research report on Tuesday. They issued a “buy” rating on the stock. Stifel Nicolaus reaffirmed a “hold” rating and issued a $7.00 price target on shares of MEI Pharma in a research note on Friday, April 12th.
Get Our Latest Research Report on MEI Pharma
MEI Pharma Stock Down 2.1 %
MEI Pharma (NASDAQ:MEIP – Get Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.01. On average, research analysts predict that MEI Pharma, Inc. will post 3.22 EPS for the current fiscal year.
Institutional Investors Weigh In On MEI Pharma
A hedge fund recently bought a new stake in MEI Pharma stock. Cable Car Capital LLC purchased a new stake in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 611,440 shares of the company’s stock, valued at approximately $3,546,000. MEI Pharma makes up 3.9% of Cable Car Capital LLC’s holdings, making the stock its 10th largest holding. Cable Car Capital LLC owned 9.18% of MEI Pharma at the end of the most recent quarter. 52.38% of the stock is currently owned by institutional investors.
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Featured Stories
- Five stocks we like better than MEI Pharma
- What Does a Stock Split Mean?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Trading Halts Explained
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Invest in Biotech Stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.